Human malaria is caused by four human-host restricted or adapted species of the genus Plasmodium, listed here in their order of risk for causing severe disease Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae – or so we thought.
Intermittent Preventive Treatment (IPT) should be provided especially among primigravid, secondigravid and younger mothers at PHC centres.
There was a considerable reduction of the proportion of malaria among fevers over time in Africa. This decline provides evidence for the policy change from presumptive anti-malarial treatment of all children with fever to laboratory diagnosis and treatment upon result.
To determine the frequency of co-infections with Plasmodium species in southern Myanmar, we investigated the prevalence of P. knowlesi.
In the present study, PfPPO has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.
In the present study, we have used indirect immunofluorescence assays and immunoelectron microscopy to demonstrate that PfASP is localized in the neck of rhoptries and not in micronemes as previously described.
Here, we give an overview of the PlasmodiumABC family members with reference to their possible role in multidrug resistance.
The optimum mixture of 6-methyl-5-hepten-2-one and geranylacetone was a 1:1 ratio and this provided the most effective protection against all species of mosquito tested. With further improvements in formulation, selected blends of these compounds have the potential to be exploited and developed as human-derived novel repellents for personal protection.
We discuss whether there are common principles governing resistance dispersal in Africa and how these might guide surveillance in future.